Compound Betamethasone for New Sarcoidosis
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests if a steroid combination medicine called Compound Betamethasone works well for people recently diagnosed with pulmonary sarcoidosis who haven't yet had treatment. The goal is to see if it can control the disease with fewer side effects than usual steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were diagnosed with pulmonary sarcoidosis within the last 3 months and have not yet been treated with any medication for it.
- Your sarcoidosis is stage I or II on a CT scan (this means it affects the lymph nodes and lungs in a certain way).
- Your diagnosis was confirmed by a small tissue sample taken during a bronchoscopy (a test where a thin tube is placed into your airways).
- Your doctor has decided that you need treatment with steroids (like prednisone) for your sarcoidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether hydroxychloroquine can control extrapulmonary sarcoidosis (sarcoidosis outside the lungs) using less steroid treatment. It may help people who need systemic therapy for problems such as eyes, skin, bones, joints, nerves, ENT areas, or high calcium levels from sarcoidosis.
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
This trial tests if people with stable sarcoidosis can safely lower their corticosteroid dose over time. It may help reduce side effects from long-term steroid use.
This trial compares two treatment durations—12 months versus 6 months—of the steroid prednisolone for people with lung sarcoidosis. It aims to see if a shorter course works just as well while reducing side effects.
This trial tests a new medicine, XTMAB-16, for people with pulmonary sarcoidosis (lung inflammation) that may also affect other parts of the body. The study first checks how the body handles different doses, then looks for signs of improvement.
Hear when a new Sarcoidosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.